Mild or Moderate Covid-19

被引:941
|
作者
Gandhi, Rajesh T. [1 ,2 ]
Lynch, John B. [3 ]
del Rio, Carlos [4 ,5 ]
机构
[1] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[4] Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30322 USA
[5] Grady Hlth Syst, Atlanta, GA USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 18期
关键词
DISEASE; 2019; COVID-19; CORONAVIRUS; CHLOROQUINE;
D O I
10.1056/NEJMcp2009249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mild or Moderate Covid-19 Covid-19 has a range of clinical manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia. Diagnosis of Covid-19 is commonly made through detection of SARS-CoV-2 RNA by PCR testing of a nasopharyngeal swab or other specimens, including saliva. Antigen tests are generally less sensitive than PCR tests but are less expensive and can be used at the point of care with rapid results. Evaluation and management of Covid-19 depend on the severity of the disease. Patients with mild disease usually recover at home, whereas patients with moderate disease should be monitored closely and sometimes hospitalized. Remdesivir and dexamethasone have demonstrated benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious (and may be harmful) and data are insufficient to recommend for or against routine use of remdesivir. Infection control efforts center on personal protective equipment for health care workers, social distancing, and testing. The diagnosis of Covid-19 is usually based on SARS-CoV-2 PCR testing of a nasopharyngeal swab or other specimen. Remdesivir and dexamethasone have benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious and data are insufficient to recommend for or against routine use of remdesivir.
引用
收藏
页码:1757 / 1766
页数:10
相关论文
共 50 条
  • [41] Quantitative plasma proteome profiling of COVID-19 patients with mild and moderate symptoms
    Jiang, He-Wei
    Tao, Sheng-Ce
    [J]. EBIOMEDICINE, 2022, 75
  • [42] A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart review
    Barber, Melissa S.
    Barrett, Richard
    Bradley, Ryan D.
    Walker, Erin
    [J]. COMPLEMENTARY THERAPIES IN MEDICINE, 2021, 63
  • [43] Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19
    Knox, Hannah B.
    Dykes, Lisa A.
    Scott, Lancer A.
    Presley, Bradley C.
    Lambert, Lara C.
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (10) : 985 - 993
  • [44] The importance of early detection of ENT symptoms in mild-to-moderate COVID-19
    Spinato, Giacomo
    Costantini, Giulio
    Fabbris, Cristoforo
    Menegaldo, Anna
    Mularoni, Francesca
    Gaudioso, Piergiorgio
    Mantovani, Monica
    Borsetto, Daniele
    Vijendren, Ananth
    Da Mosto, Maria Cristina
    Boscolo-Rizzo, Paolo
    [J]. ACTA OTORHINOLARYNGOLOGICA ITALICA, 2021, 41 (02) : 101 - 107
  • [45] Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank
    Frank, Michael
    [J]. FUTURE MICROBIOLOGY, 2022, 17 (03) : 157 - 159
  • [46] Worsening of asthma control after recovery from mild to moderate COVID-19
    Kwok, Wang Chun
    Tam, Terence Chi Chun
    Lam, David Chi Leung
    Leung, Jackson Ka Chun
    Chan, King Pui Florence
    Chan, Shung Kay Samuel
    Chiang, Ka Yan
    Ip, Mary Sau Man
    Ho, James Chung Man
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [47] Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19
    Al-kuraishy, Hayder M.
    Al-Gareeb, Ali I.
    Alarfaj, Sumaiah J.
    Al-Akeel, Rasha Khalifah
    Faidah, Hani
    El-Bouseary, Maisra M.
    Sabatier, Jean-Marc
    De Waard, Michel
    El-Masry, Thanaa A.
    Batiha, Gaber El-Saber
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [48] Prediction of the Rehabilitation Duration and Risk Management for Mild-Moderate COVID-19
    Zheng, Qiong-Na
    Xu, Mei-Yan
    Zheng, Yong-Le
    Wang, Xiu-Ying
    Zhao, Hui
    [J]. DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2020, 14 (05) : 652 - 657
  • [49] Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
    Martin, David E.
    Pandey, Neelam
    Chavda, Purvi
    Singh, Gurpreet
    Sutariya, Rakesh
    Sancilio, Frederic
    Tripp, Ralph A.
    [J]. VIRUSES-BASEL, 2023, 15 (07):
  • [50] Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19
    Hayder M. Al-kuraishy
    Ali I. Al-Gareeb
    Sumaiah J. Alarfaj
    Rasha Khalifah Al-Akeel
    Hani Faidah
    Maisra M. El-Bouseary
    Jean-Marc Sabatier
    Michel De Waard
    Thanaa A. El-Masry
    Gaber El-Saber Batiha
    [J]. Scientific Reports, 13